Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...
Screenshot of PathAI's AIM-MASH AI Assist in action. An artificial intelligence model developed by PathAI – used to help diagnose metabolic dysfunction associated steatohepatitis (MASH) from liver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback